(4S)-3-[(2E)-3-(4-Methylphenyl)prop-2-enoyl]-4-phenyl-1,3-oxazolidin-2-one

Catalog No. :
ACKYYC062
CAS No. :
915390-74-8
Molecular Formula :
C19H17NO3
Molecular Weight :
307.35

IUPAC Name:(S,E)-4-phenyl-3-(3-(p-tolyl)acryloyl)oxazolidin-2-one

(4S)-3-[(2E)-3-(4-Methylphenyl)prop-2-enoyl]-4-phenyl-1,3-oxazolidin-2-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5mg97%$120.00Login to see priceInquiryInquiry
10mg97%$147.00Login to see priceInquiryInquiry
250mg97%$211.00Login to see priceInquiryInquiry
1g97%$302.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(4S)-3-[(2E)-3-(4-Methylphenyl)prop-2-enoyl]-4-phenyl-1,3-oxazolidin-2-one
IUPAC Name(S,E)-4-phenyl-3-(3-(p-tolyl)acryloyl)oxazolidin-2-one
MDL No.MFCD22126134
Molecular FormulaC19H17NO3
Molecular Weight307.35
SMILESO=C1OC[C@H](C2=CC=CC=C2)N1C(/C=C/C3=CC=C(C)C=C3)=O
InChI KeyIPXSZYICVIVCPJ-FMQWLBJXSA-N
Synonym(4S)-3-[(2E)-3-(4-Methylphenyl)prop-2-enoyl]-4-phenyl-1,3-oxazolidin-2-one;2-Oxazolidinone, 3-[(2E)-3-(4-methylphenyl)-1-oxo-2-propen-1-yl]-4-phenyl-, (4S)-;(S,E)-4-phenyl-3-(3-(p-tolyl)acryloyl)oxazolidin-2-one
CAS No.915390-74-8

Synthetic Route by SureRoute

1. ACKYYC062 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEOSI625 route compound structure diagram
    ACEOSI625940-61-4 In Stock
  2. Plus
  3. ACUZMA624 route compound structure diagram
    ACUZMA62499395-88-7 In Stock
  4. Then
  5. ACKYYC062 route product structure diagram
    ACKYYC062915390-74-8
Inquiry

2. ACKYYC062 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACCKPY028 route compound structure diagram
    ACCKPY02813565-07-6 In Stock
  2. Plus
  3. ACUZMA624 route compound structure diagram
    ACUZMA62499395-88-7 In Stock
  4. Then
  5. ACKYYC062 route product structure diagram
    ACKYYC062915390-74-8
Inquiry

Comments (0)